Gilead Sciences is letting go of 114 employees based out of the company’s Morris Plains, New Jersey facility following an underwhelming response to the results reaped so far from the $21 billion acquisition of Immunomedics in 2020, according to BioSpace.
BioNTech announced an expansion of a collaboration with Regeneron Pharmaceuticals to continue advancing mRNA technology and develop the FixVac candidate BNT116 in combination with Regeneron and Sanofi’s shared pharmaceutical product Libtayo (cemiplimab) for non-small cell lung cancer.
Pharma giant AbbVie and Iceland-based Alvotech settled a case filed with the International Trade Commission. The dispute centered around Alvotech’s adalimumab biosimilar drug, which AbbVie posited had been developed through theft of trade secrets of the company’s Humira product.
Bristol Myers Squibb’s blockbuster cancer drug Revlimid finally has a competitor as Teva Pharmaceuticals announced the launch of a generic version of Revlimid, which could significantly cut into the global biopharmaceutical company’s earnings.
Katie Couric, award winning journalist and colorectal cancer advocate who normalized talking about colon cancer more than two decades ago, announced she teamed up with Cologuard® maker Exact Sciences to highlight the urgent need for people to get screened.
A late-stage study of Gilead Sciences’ antibody-drug conjugate Trodelvy shows promise in slowing disease progression in some of the most common forms of breast cancer.
The U.S. Food and Drug Administration placed a partial clinical hold on Alpine Immune Sciences’ NEON-2 trial, which is evaluating davoceticept (ALPN-202) in combination with Merck’s immunotherapy pembrolizumab (Keytruda) in adults with cancer.
The U.S. Food and Drug Administration approved the expanded use of Bristol Myers Squibb’s cancer drug Opdivo along with chemotherapy as treatment that patients with an aggressive form of lung cancer receive before surgery.
Atlas Venture successfully raised $450 million at the close of the venture capital firm’s thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.